Research Group
Prostate and Urologic Cancer
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Status
Active, not recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT04300855
This randomized double-blinded Phase II clinical trial will evaluate the bioavailability, safety, effectiveness and validate the mechanism by which a standardized formulation of whole Green Tea Catechin, (Sunphenon® 90D) containing 405 mgs vs. Placebo, administered for 24 months in a cohort of men with low to intermediate grade prostate managed on active surveillance
Intervention
Placebo, Sunphenon
Condition
Prostate Cancer, Prostate Adenocarcinoma
Investigators
Nagi Kumar, PhD, RD, FADA